UB Paderborn / Katalog / Suche / in CDI

Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex ® Growth Forum Database Registry

Frontiers in endocrinology (Lausanne), 2022-02, Vol.13, p.812568

2022

Volltextzugriff (PDF)

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

European journal of cancer (1990), 2021-01, Vol.142, p.102-111

2021

Volltextzugriff (PDF)

The Coactivator p300 Directly Acetylates the Forkhead Transcription Factor Foxo1 and Stimulates Foxo1-Induced Transcription

Molecular endocrinology (Baltimore, Md.), 2005-09, Vol.19 (9), p.2283-2298

2005

Volltextzugriff (PDF)

Plexin B Regulates Rho through the Guanine Nucleotide Exchange Factors Leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF

The Journal of biological chemistry, 2002-11, Vol.277 (45), p.43115-43120

2002

Volltextzugriff (PDF)

Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study

Therapeutic advances in urology, 2017-07, Vol.9 (7), p.179-190

2017

Volltextzugriff (PDF)

Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro

Neuromolecular medicine, 2014-12, Vol.16 (4), p.752-771

2014

Volltextzugriff (PDF)

Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy

Therapeutic advances in urology, 2018-12, Vol.10 (12), p.365-376

2018

Volltextzugriff (PDF)

EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin‐releasing hormone agonist for prostate cancer

BJUI compass, 2022-01, Vol.3 (1), p.45-54

2022

Volltextzugriff (PDF)

MacAB-TolC Contributes to the Development of Acinetobacter baumannii Biofilm at the Solid-Liquid Interface

Frontiers in microbiology, 2022-01, Vol.12, p.785161-785161

2022

Volltextzugriff (PDF)

CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS740-TPS740

2023

Volltextzugriff (PDF)

Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment

CNS & neurological disorders drug targets, 2021-01, Vol.20 (4), p.378

2021

Volltextzugriff (PDF)

Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1−/– mice

Genes to cells : devoted to molecular & cellular mechanisms, 2006-12, Vol.11 (12), p.1337-1352

2006

Volltextzugriff (PDF)

1701: Compliance to a 1-year triptorelin treatment in real life, TALISMAN final analysis (NCT04593420)

Radiotherapy and oncology, 2024-05, Vol.194, p.S2445-S2448

2024

Volltextzugriff (PDF)

Main reasons of choice of formulation and route of triptorelin treatment initiated in patients with prostate cancer (PCa): TALISMAN study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.104-104

2023

Volltextzugriff (PDF)

CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.626-626

2023

Volltextzugriff (PDF)

Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS744-TPS744

2023

Volltextzugriff (PDF)

Effectiveness and Overall Safety of NutropinAq ® for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq ® European Registry (iNCGS)

Frontiers in endocrinology (Lausanne), 2021-05, Vol.12, p.676083-676083

2021

Volltextzugriff (PDF)

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4530-4530

2023

Volltextzugriff (PDF)

CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4529-4529

2023

Volltextzugriff (PDF)

CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2

The Journal of neuroscience, 2010-08, Vol.30 (32), p.10639-10654

2010

Volltextzugriff (PDF)

CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.606-606

2023

Volltextzugriff (PDF)

Characterization of Insulin Inhibition of Transactivation by a C-terminal Fragment of the Forkhead Transcription Factor Foxo1 in Rat Hepatoma Cells

The Journal of biological chemistry, 2003-07, Vol.278 (28), p.26111-26119

2003

Volltextzugriff (PDF)

Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy: Subgroup analysis of EQUINOXE study

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.232-232

2020

Volltextzugriff (PDF)

Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16512-e16512

2023

Volltextzugriff (PDF)

MP22-13 IMPACT OF RELATIONAL COHESION AND SEXUALITY ON THE QUALITY OF LIFE OF PATIENTS TREATED WITH GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST FOR PROSTATE CANCER: FINAL ANALYSIS OF THE EQUINOXE STUDY

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex ® Growth Forum Database Registry

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

The Coactivator p300 Directly Acetylates the Forkhead Transcription Factor Foxo1 and Stimulates Foxo1-Induced Transcription

Plexin B Regulates Rho through the Guanine Nucleotide Exchange Factors Leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF

Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study

Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro

Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy

EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin‐releasing hormone agonist for prostate cancer

MacAB-TolC Contributes to the Development of Acinetobacter baumannii Biofilm at the Solid-Liquid Interface

CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma

Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment

Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1−/– mice

1701: Compliance to a 1-year triptorelin treatment in real life, TALISMAN final analysis (NCT04593420)

Main reasons of choice of formulation and route of triptorelin treatment initiated in patients with prostate cancer (PCa): TALISMAN study

CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy

Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS)

Effectiveness and Overall Safety of NutropinAq ® for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq ® European Registry (iNCGS)

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy

CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC)

CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2

CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC)

Characterization of Insulin Inhibition of Transactivation by a C-terminal Fragment of the Forkhead Transcription Factor Foxo1 in Rat Hepatoma Cells

Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy: Subgroup analysis of EQUINOXE study

Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study

MP22-13 IMPACT OF RELATIONAL COHESION AND SEXUALITY ON THE QUALITY OF LIFE OF PATIENTS TREATED WITH GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST FOR PROSTATE CANCER: FINAL ANALYSIS OF THE EQUINOXE STUDY

Suchergebnisse filtern